Sharathchandra S. Hegde is VP at Theravance Biopharma, Inc. (TBPH). They have made 1 open-market trade across 1 company since 2019, most recently 2019-08-20.
CIK 0001668696
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TBPH | 259,900 | $4.4M |
Shares reported on the most recent Form 4, priced at the 2019-08-22 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TBPH | SELL | 2019-03-04 | 2019-03-06 | $24.80 | $307K | +5.9% | +6.2% | -26.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.